检索结果-南通市图书馆

Journal of Pharmaceutical Analysis 2021年第2期11卷 155-162页

作者： Ming-Rui Shen Yi He Shang-Mei Shi chinese pharmacopoeia Commission No.11 Fahua NanliBeijing100061China

As an important branch of medicine, Traditional chinese Medicine(TCM) has been applied for the treatment of diseases for thousands of years in China and other countries in East Asia. The chinese pharmacopoeia(ChP) is a drug code formulated by the chinese government, and it includes a special volume for the monographs of TCM, which plays an important role in ensuring the quality of drugs. The use of quality control technology has always been a complex and important factor in TCM. Owing to the chemical diversity of TCM, chromatography technology has been proven to be a comprehensive strategy for the assessment of the overall quality of TCM and has become the main analytical method in the *** article provides an overview of the classical and modern chromatographic technologies applied in the ChP, and summarizes the advantages and disadvantages of each technique in the TCM *** 2020, the new edition of the Ch P(the 2020 edition) has been implemented at the end of 2020. This paper also contains a brief introduction about the application of chromatographic technologies in the new edition of the ChP.

关键词： Traditional chinese medicine chinese pharmacopoeia Chromatographic technology Quality control

Development of the general chapters of the chinese pharmacopoeia 2020 edition: A review

在线全文

学校读者我要写书评

暂无评论

Journal of Pharmaceutical Analysis 2021年第4期11卷 398-404页

作者： Xinyi Xu Huayu Xu Yue Shang Ran Zhu Xiaoxu Hong Zonghua Song Zhaopeng Yang chinese pharmacopoeia Commission Beijing100061China

The chinese pharmacopoeia 2020 edition was reviewed and approved by the National Medical Products Administration and the National Health Commission of the People’s Republic of China in July *** current edition was officially implemented on December 30,*** general chapters of the chinese pharmacopoeia discuss the general testing methods and guidelines,which are the common requirements and basis for the implementation of drug standards in the chinese *** to adherence to the principles of scientificity,versatility,operability,and sustainable development,there is an improvement in the general chapters of the 2020 edition over those of the previous ***,the application of advanced and mature analytical techniques has expanded,the development of testing methods for exogenous pollutants in traditional chinese medicines has been strengthened,and technical requirements are now better harmonized with international *** updated edition provides technical and methodological support to ensure safety,effectiveness,and control of pharmaceuticals in China and will play an important and active role in encouraging the application of advanced technologies,improving the quality control of medicines,and strengthening the means of drug regulation in *** review provides a comprehensive introduction of the main features of and changes to the general chapters in the chinese pharmacopoeia 2020 edition and aims to provide reference for its correct understanding and accurate implementation.

关键词： chinese pharmacopoeia 2020 edition General chapter Development Review

New Collection of Crude Drugs in chinese pharmacopoeia 2010 Ⅰ.Callicarpa Linn. and Related Items

在线全文

学校读者我要写书评

暂无评论

chinese Herbal Medicines 2010年第4期02卷 272-288页

作者： DAN Yang1, QIAN Zhong-zhi2, LIU Yan-ze1, ZHOU Guo-ping3, PENG Yong1, XIAO Pei-gen1 1. Institute of Medicinal Plant Development, chinese Academy of Medical Science, Beijing 100193, China 2. China pharmacopoeia Committee, Beijing 100061, China 3. Jiangxi Provincial Institute for Food and Drug Control, Nanchang 330046, China Institute of Medicinal Plant Development Chinese Academy of Medical ScienceBeijing 100193China China pharmacopoeia Committee Beijing 100061China Jiangxi Provincial Institute for Food and Drug Control Nanchang 330046China

Callicarpa Linn. (beautyberry) is one of the major genera in Verbenaceae, about 20 of which are medicinal plants. Beautyberry, called Zizhu in China, is a generic name of those species and largely used as hemostatic medicine. The chinese pharmacopoeia 2010 has admitted three new crude drugs from the genus of Callicarpa Linn. including Callicarpae Macrophyllae Folium, Callicarpae Caulis et Folium, and Callicarpae Formosanae Folium for the first time since the 1977 version of the chinese pharmacopoeia. In order to better understand these new crude drugs, we systematically described their bibliography, admission reasons, botanical identification, chemistry, and pharmacology. Several other species, out of national regulations but intensively studied and widely used, are also covered in this review.

关键词： Callicarpa formosana Callicarpa kwangtungensis Callicarpa Linn. Callicarpa macrophylla chinese patent medicine chinese pharmacopoeia quality assessment

New Collection of Crude Drugs in chinese pharmacopoeia 2010 ***(Berberis spp.)

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

chinese Herbal Medicines 2011年第4期3卷 268-284页

作者： DAN Yang1,LIU Yan-ze1,PENG Yong1,QIAN Zhong-zhi2,XIAO Pei-gen1 1.Institute of Medicinal Plant Development,chinese Academy of Medical Sciences,Beijing 100193,China 2.chinese pharmacopoeia Commission,Beijing 100061,China

Sankezhen(Berberidis Radix)is a traditional chinese materia medica,cold in nature and bitter in taste,for treating syndromes of liver,stomach,and large intestinal meridians,in which berberine and berbamine are the major pharmacological *** has been readmitted in chinese pharmacopoeia 2010 following the 1977 version as the roots of Berberis ***,***,***,***,*** studies showed that Berberis *** potential phytomedicines with multiple spectrums therapeutic effects and various pharmaceutical *** we reviewed Sankezhen in traditional use and phytochemistry,and its major active components berberine and berbamine with potential bioactivities recently discovered,such as antitumor,antidiabetic, antihyperlipidemic,anti-arrhythmic,and neuro-protective *** is necessary to mature the quality assessment of Sankezhen as a new admission of chinese pharmacopoeia *** parts of Berberis *** be investigated to better develop this herb in medicinal usage.

关键词： alkaloids Berberidis Radix berberine berbamine chinese pharmacopoeia ethnopharmacology

Medicinal plants of chinese pharmacopoeia and Daodi:Insights fromphylogeny and biogeography

在线全文

学校读者我要写书评

暂无评论

chinese Herbal Medicines 2018年第3期10卷 269-278页

作者： Di Lei Jie wu Christine Leon Lin-fang Huang Julie A.Hawkins School of Biological Sciences University of ReadingReading RC6 6BXUnited Kingdom Institute of chinese Materia Mediea China Academy of Chinese Medical SciencesBeijing 100700China Royol Botanic Gardens KewRichmondSurrey TW9 3ABUnited Kingdom Institute of Medicinal Plant Development Peking Union Medical College&Chinese Academy of Medical SciencesBeijing 100193China

Objective: The chinese pharmacopoeia(2015) includes 584 plant medicines, of which 284 also contain high quality subsets, so called "Daodi" components, where Daodi denotes superior clinical properties compared to non-Daodi counterparts despite being sourced from the same species. Commercial and clinical drivers of selection for Daodi have been described elsewhere. Our objective is to investigate the overall composition of Daodi to determine in what ways medicines with Daodi as a whole differ from the other plants of the chinese pharmacopoeia. A further objective is to characterise the chinese pharmacopoeia and Daodi in terms of the plant species including their traits and ***: We used trait analysis to identify whether Daodi species were significantly different from the remaining chinese pharmacopoeia plant species in any traits. We used biogeographic methods and an existing classification of Daodi into 10 regions to identify spatial patterns amongst the species. Regression and binomial analyses were used to test for over-and under-use of plant families and endemic *** for lineages were visualized using phylogenetic ***: We found that Daodi species(species with any Daodi subset) were more likely to be roots that are "hot" or "warm", and less likely to be "oxic", according to traditional chinese medicine(TCM) concepts. Roots were over-represented in the Bei region, and whole plants over-represented in Guang. Both the chinese pharmacopoeia and Daodi indicated preferences for families not common in previously studied ethnopharmacopoeias, and fewer endemic species were represented than expected by ***: Using the phylogenetic and biogeographical methods, we highlighted patterns of plant use,and the biological characters of Daodi medicinal plants. Our study points towards cultural preferences in need of scientific explanation.

关键词： biogeography chinese pharmacopoeia Daodi phylogeny

DNA barcoding database for chinese pharmacopoeia

在线全文

学校读者我要写书评

暂无评论

DNA barcoding database for Chinese Pharmacopoeia

Review on“Long-Dan”,one of the traditional chinese medicinal herbs recorded in chinese pharmacopoeia

第一届《药学学报》药学前沿论坛暨2015年中国药学会中药与天然药物专业委员会会议

作者：姚辉 SONG Jing-yuan SHI Lin-chun HAN Jian-ping SUN Wei CHEN Shi-lin Institute of Medicinal Plant Development Chinese Academy of Medical Sciences & Peking Union Medical College Institute of chinese Materia Medica China Academy of Chinese Medical Sciences

In recent years,traditional identification methods(botanical source and morphological identification,microscopic identification,and physiochemical identification) have been unable to meet the demands of rapid development in China’s pharmaceutical *** barcoding technology emerged in 2003 and revolutionized the available identification *** team proposed and verified that nuclear ITS2 is suitable to identify traditional chinese medicines(TCMs).A novel identification system for chinese herbal medicines in chinese pharmacopoeia(ChP),which employs DNA barcodes,was set up and has been adopted in the latest ChP(2015edition).However,systematic research on identification of TCMs in ChP by using DNA barcoding remains *** this study,we established a DNA barcoding database for medicinal species in ChP(http://***/en/).One sample of original species and three samples of medicinal materials were available for each chinese Materia *** of the samples were collected from China,whereas some of them were collected from other countries,such as Japan,Korea,Canada,and the United *** date,six different modules have been implemented in the web server,***,Protocol,Database,News,Documents,and *** the Identification module,nr ITS2 was the core DNA barcode for identifying medicinal plants,whereas the psbA-trnH region was a complementary *** was used to identify medicinal *** database provides standard sequences for each medicinal species in ChP,thereby contributing great practical significance to clinical safety in utilization of ***,this system can help prevent illegal drug trade in circulation.

关键词： chinese Materia Medica DNA barcoding ITS2 identification chinese pharmacopoeia

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

Natural Products and Bioprospecting 2012年第1期2卷 1-10页

作者： Yan-Ming WANG Min XU Dong WANG Hong-Tao ZHU Chong-Ren YANG Ying-Jun ZHANG State Key Laboratory of Phytochemistry and Plant Resources in West China Kunming Institute of BotanyChinese Academy of SciencesKunming 650201China Graduate University of chinese Academy of Sciences Beijing 100049China Weihe Biotech Laboratory Yuxi 653100China

“Long-Dan”is an important traditional chinese medicinal(TCM)herb used widely for the treatment of inflammation,hepatitis,rheumatism,cholecystitis,and *** the chinese pharmacopoeia,the roots and rhizomes of four species from the genus Gentiana(Gentianaceae)are recorded as the original materials of“Long-Dan”,called Gentianae Radix et *** species included ***,***,*** and ***,which are distributed in different areas of *** iridoid and secoiridoid glucosides were reported as the main constituents in“Long-Dan”,these four different species also resulted in different minor components,which may related to their pharmacological ***,we summarized the herbal textual study,distribution,chemical constituents,biological investigation and quality control of the recorded“Long-Dan”origins in chinese pharmacopoeia during the period 1960 to 2011.

关键词： Long-Dan chinese pharmacopoeia herbal textual study chemistry bioactivity quality control

Comparison of Sulfur Dioxide Residue in chinese Me-dicinal Materials by Titration-fluorescence Spectrome-try and pharmacopoeia Method

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Animal Husbandry and Feed Science 2017年第2期9卷 112-114页

作者： Ma Donglai Shen Zhengxian Du Huiru Zhang Zhidong Jiang Cuilan Wang Liang Li Jing Zheng Yuguang College of Pharmacy Hebei University of Chinese MedicineShijiazhuang 050200China Hebei Development Center of Traditional chinese Medicine Shiji-azhuang 050051China Hebei Chemical&Pharmaceutical College Shijiazhuang 050026China

With sulphur-fumigated chinese medicinal materials （Fritillaria thunbergii , Isatis #utigotica , Asparagus cochinchinensis and Poria cocos ） as the test materials, sulfur dioxide or sulfite residue was determined by the method in chinese pharmacopoeia （2015 edition） and titration-fluorescence spectrometry, respec- tively. The results showed that there were significant differences in measured value between titration-fluorescence spectrometry and phmmacopoeia method. The t result of titration-fluorescence spectrometry was much closer to the actual content of sulfur dioxide in chinese medicinal materials. Thus, titration-fluo- rescence spectrometry had higher application value

关键词： Titration-fluorescence spectrometry chinese pharmacopoeia Sulfur dioxide chinese medicinal materials Residue